EBRANTIL Side Effects

6551511-4 | Agitation, Dyspnoea, Hypertensive Crisis, Hypoxia, Malaise
on Jan 14, 2010 Female patient from ITALY , weighting 132.3 lb, was diagnosed with nuclear magnetic resonance imaging and was treated with Ebrantil (View Usage). Patient experienced the following unwanted or unexpected effects: agitation, dyspnoea, hypertensive crisis, hypoxia, malaise. Ebrantil dosage: . During the same period patient was treated with OXYGEN (View Oxygen Review and Oxygen Label ), LASIX (View Lasix Review and Lasix Label ), CETIRIZINE HCL (View Cetirizine Hcl Review and Cetirizine Hcl Label ), DELTACORTENE (View Deltacortene Review and Deltacortene Label ), RANITIDINA (View Ranitidina Review and Ranitidina Label ), MULTIHANCE (View Multihance Review and Multihance Label ). Patient was hospitalized.

5875557-4 | Hepatocellular Injury, Malaise
Patient was taking Ebrantil (View Usage). Patient had the following side effects: hepatocellular injury, malaise on Aug 29, 2008 from JAPAN Additional patient health information: Female patient , 50 years of age, was diagnosed with insomnia and. Ebrantil dosage: Unk. During the same period patient was treated with MYSLEE (View Myslee Review and Myslee Label ).

5743559-4 | Blood Albumin Decreased, Blood Amylase Increased, Blood Cholinesterase Decreased, Blood Glucose Increased, Blood Lactate Dehydrogenase Increased, Blood Potassium Increased, Blood Urea Increased, Blood Uric Acid Decreased, C-reactive Protein Increased
Adverse event was reported on May 14, 2008 by a Male patient taking Ebrantil (View Usage) (Dosage: 30 Mg, Unk) was diagnosed with benign prostatic hyperplasia, cerebral infarction, hypertension, dizziness (What is dizziness?) and. Location: JAPAN , 79 years of age, weighting 143.3 lb, After Ebrantil was administered, patient had the following side effects: blood albumin decreased, blood amylase increased, blood cholinesterase decreased, blood glucose increased, blood lactate dehydrogenase increased, blood potassium increased, blood urea increased, blood uric acid decreased, c-reactive protein increased. During the same period patient was treated with KETAS (10 Mg, Unk) (View Ketas Review and Ketas Label ), ENDOXAN (View Endoxan Review and Endoxan Label ), ELASPOL (View Elaspol Review and Elaspol Label ), PLAVIX (50 Mg Daily) (View Plavix Review and Plavix Label ), DIOVAN (80 Mg Once Daily) (View Diovan Review and Diovan Label ), MERISLON (36 Mg, Unk) (View Merislon Review and Merislon Label ), URIEF (4 Mg, Unk) (View Urief Review and Urief Label ). Patient was hospitalized.

4710946-2 | Cardiac Failure Congestive, Dyspnoea
on Jun 06, 2005 Female patient from JAPAN , 69 years of age, was diagnosed with neurogenic bladder, diabetes mellitus, constipation (What is constipation?), depression (What is depression?) and was treated with Ebrantil (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac failure congestive, dyspnoea. Ebrantil dosage: 15 Mg, Unk. During the same period patient was treated with BASEN (0.3 Mg, Tid) (View Basen Review and Basen Label ), MAGNESIUM OXIDE (1 G, Unk) (View Magnesium Oxide Review and Magnesium Oxide Label ), TOLEDOMIN (50 Mg, Unk) (View Toledomin Review and Toledomin Label ), FASTIC (270 Mg, Unk) (View Fastic Review and Fastic Label ), RISPERDAL (1 Mg, Unk) (View Risperdal Review and Risperdal Label ). Patient was hospitalized.


4692800-8 | Cardiac Failure Congestive, Dyspnoea
on Jun 06, 2005 Female patient from , 69 years of age, was diagnosed with neurogenic bladder, diabetes mellitus, constipation (What is constipation?), depression (What is depression?) and was treated with Ebrantil (View Usage). Patient had the following side effects: cardiac failure congestive, dyspnoea. Ebrantil dosage: 15 Mg, Unk. During the same period patient was treated with BASEN (0.9 Mg, Unk) (View Basen Review and Basen Label ), MAGNESIUM OXIDE (1 G, Unk) (View Magnesium Oxide Review and Magnesium Oxide Label ), TOLEDOMIN (50 Mg, Unk) (View Toledomin Review and Toledomin Label ), FASTIC (270 Mg, Unk) (View Fastic Review and Fastic Label ), RISPERDAL (1 Mg, Unk) (View Risperdal Review and Risperdal Label ). Patient was hospitalized.

4687216-4 | Cardiac Failure
Patient was taking Ebrantil (View Usage). After Ebrantil was administered, patient had the following side effects: cardiac failure on Jun 06, 2005 from Additional patient health information: Female patient , 69 years of age, was diagnosed with depression (What is depression?) and. Ebrantil dosage: 15 Mg, Unk. During the same period patient was treated with BASEN (View Basen Review and Basen Label ), MAGNESIUM OXIDE (View Magnesium Oxide Review and Magnesium Oxide Label ), TOLEDOMIN (View Toledomin Review and Toledomin Label ), FASTIC (270 Mg, Unk) (View Fastic Review and Fastic Label ).